BioLife Solutions, Inc. (BLFS) 

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

Show less

Over the last 12 months, insiders at BioLife Solutions, Inc. have bought $11.15M and sold $3.25M worth of BioLife Solutions, Inc. stock.

On average, over the past 5 years, insiders at BioLife Solutions, Inc. have bought $32.59M and sold $57.39M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Casdin Partners Master Fund, L.P. (10 percent owner) — $55.73M.

The last purchase of 927,165 shares for transaction amount of $10.37M was made by Casdin Partners Master Fund, L.P. (10 percent owner) on 2023‑10‑19.